Policy & Regulation
Karyopharm seeks accelerated FDA approval for selinexor–ruxolitinib in myelofibrosis
31 August 2026 - US pharmaceutical company Karyopharm Therapeutics Inc. (NASDAQ: KPTI) said on Monday it has submitted a supplemental New Drug Application to the US Food and Drug Administration for Ac...
Lilly to acquire Merida Biosciences in USD2.875bn deal
31 August 2026 - US pharmaceutical company Eli Lilly and Company (NYSE: LLY) on Monday announced that it has agreed to acquire Merida Biosciences, Inc., a biotechnology business developing precision b...
Harvest Integrated Research Organization signs MoU with Differentia Biotech
31 August 2026 - Harvest Integrated Research Organization (HiRO), a full-service global clinical research organisation, announced on Friday that it has signed a Memorandum of Understanding (MOU) for i...
Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30
31 August 2026 - Ascletis Pharma Inc. (Ascletis) (HKEX: 1672), a fully integrated biotechnology company, announced on Sunday that it has dosed its first participant in a global Phase III clinical prog...
Zambon receives European Commission approval for Hopledo in Parkinson's disease
28 August 2026 - Italian pharmaceutical company Zambon announced on Friday that the European Commission has granted marketing authorisation for Hopledo, a first-in-class oral, modified-release formula...
Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial
28 August 2026 - Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company based in Sydney, Australia, announced on Thursday new data showing that its lead asset, paxalisi...